Together, these analyses identify CD8+ T cells as a protective immune component and CCL18 as an independent adverse prognostic factor in ABC DLBCL, with both findings validated in an independent patient cohort, supporting their potential clinical utility for risk stratification. The gene discussed is CD8A; the disease is diffuse large B-cell lymphoma.